#Authors submission trial

EIJ ranks 1 st among interventional cardiology journals in terms of scholarly impact based on Altmetric Score.

Worldwide reach and visibility through the media channels of EIJ, including PCRonline (website and newsletters), Facebook and Twitter.

Prompt indexing in MEDLINE®/PubMed®, Science Citation Index® (ISI), SciVerse, Scopus.

Ahead of print publication (AOP)with DOI assignment, fully proofed and formatted in the style of the Journal.

Manuscripts accepted by EIJ benefit from: Rapid editorial decisions for manuscripts that do not pass the initial screening phase and are typically returned to the authors in 1 to 3 business days from submission without external peer review. Manuscripts submitted to EIJ benefit from:Ī high-standard, single blind peer-review service that is typically completed from submission to decision in 4 weeks for manuscripts that are sent out for external peer review.

With a 2021 impact factor of 7.728, access to state-of-the-art media at PCRonline and the journal’s own website, EIJ is at the cutting edge of scientific publications in interventional cardiology today. Since its inception in 2005, the mission of EIJ has been to bring healthcare providers research studies that foster innovation in interventional cardiology and add value to clinical practice.

EIJ is the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Case reports are not considered for publication except when they include striking images of significant educational value in the form of “Interventional flashlights”.

#Authors submission trial

In addition to clinical and translational research studies, EIJ publishes state-of-the-art reviews, meta-analyses, expert consensus documents, trial design papers, short reports, editorials and viewpoints. EIJ publishes peer-reviewed articles in English over the entire spectrum of diagnostics and interventions in cardiovascular medicine.